Cumberland Pharmaceuticals Inc. (CPIX)
CPIX Stock Price Chart
Explore Cumberland Pharmaceuticals Inc. interactive price chart. Choose custom timeframes to analyze CPIX price movements and trends.
CPIX Company Profile
Discover essential business fundamentals and corporate details for Cumberland Pharmaceuticals Inc. (CPIX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
11 Aug 2009
Employees
91.00
Website
https://www.cumberlandpharma.comCEO
A. J. Kazimi MBA
Description
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.
CPIX Financial Timeline
Browse a chronological timeline of Cumberland Pharmaceuticals Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 4 Nov 2025
Earnings released on 5 Aug 2025
EPS came in at $0.02 , while revenue for the quarter reached $10.84M .
Earnings released on 6 May 2025
EPS came in at $0.16 , while revenue for the quarter reached $11.71M .
Earnings released on 4 Mar 2025
EPS came in at -$0.02 , while revenue for the quarter reached $10.44M .
Earnings released on 7 Nov 2024
EPS came in at -$0.02 , while revenue for the quarter reached $9.09M .
Earnings released on 6 Aug 2024
EPS came in at $0.01 , while revenue for the quarter reached $9.85M .
Earnings released on 7 May 2024
EPS came in at -$0.05 , while revenue for the quarter reached $8.50M .
Earnings released on 5 Mar 2024
EPS came in at -$0.11 , while revenue for the quarter reached $9.35M .
Earnings released on 7 Nov 2023
EPS came in at $0.02 , while revenue for the quarter reached $10.09M .
Earnings released on 8 Aug 2023
EPS came in at $0.16 , while revenue for the quarter reached $10.89M .
Earnings released on 9 May 2023
EPS came in at $0.11 , while revenue for the quarter reached $9.22M .
Earnings released on 7 Mar 2023
EPS came in at -$0.05 , while revenue for the quarter reached $9.12M , beating expectations by +13.01%.
Earnings released on 8 Nov 2022
EPS came in at $0.10 , while revenue for the quarter reached $11.41M , beating expectations by +41.37%.
Earnings released on 9 Aug 2022
EPS came in at -$0.01 , while revenue for the quarter reached $10.30M .
Earnings released on 10 May 2022
EPS came in at $0.03 , while revenue for the quarter reached $11.18M , beating expectations by +21.60%.
Earnings released on 8 Mar 2022
EPS came in at -$0.13 falling short of the estimated -$0.01 by -1.20K%, while revenue for the quarter reached $8.32M , missing expectations by -31.70%.
Earnings released on 9 Nov 2021
EPS came in at -$0.02 , while revenue for the quarter reached $8.07M , missing expectations by -12.16%.
Earnings released on 10 Aug 2021
EPS came in at $0.08 surpassing the estimated -$0.07 by +216.16%, while revenue for the quarter reached $9.06M , beating expectations by +0.01%.
Earnings released on 11 May 2021
EPS came in at $0.07 surpassing the estimated -$0.07 by +200.00%, while revenue for the quarter reached $10.54M , beating expectations by +23.97%.
Earnings released on 9 Mar 2021
EPS came in at $0.01 surpassing the estimated $0.00 by +200.30%, while revenue for the quarter reached $10.26M , beating expectations by +4.92%.
Earnings released on 10 Nov 2020
EPS came in at $0.02 surpassing the estimated -$0.07 by +128.57%, while revenue for the quarter reached $9.25M , missing expectations by -51.39%.
CPIX Stock Performance
Access detailed CPIX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.